JNJ SEC Filings
SEC filings for JNJ. Annual and quarterly reports, 8-K events, Form 4 insider filings and 13D/G stake disclosures.
| Form | Filed | Accession |
|---|---|---|
| 10-QAIThe MD&A is mostly a backward-looking, factual account of solid operational sales growth (6.0%) led by oncology, TREMFYA and neuroscience launches. | Oct 22, 2026 | 0000200406-26-000197EDGAR |
| 10-Q | Jul 23, 2026 | 0000200406-26-000153EDGAR |
| 10-QAIManagement reports solid Q1 2026 sales growth (+9.9%, 6.4% operational), driven by oncology, TREMFYA and MedTech cardiovascular. | Apr 22, 2026 | 0000200406-26-000087EDGAR |
SEC filings for companies related to JNJ
Never miss a JNJ filing.
Get an email when JNJ files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.